US SB99 | 2019-2020 | 116th Congress
Status
Spectrum: Moderate Partisan Bill (Democrat 8-1)
Status: Introduced on January 10 2019 - 25% progression, died in committee
Action: 2019-01-10 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 10 2019 - 25% progression, died in committee
Action: 2019-01-10 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Makes a series of changes relating to the prices of prescription drugs under the Medicare prescription drug benefit and Medicare Advantage (MA) prescription drug plans (PDPs). Under current law, the Centers for Medicare & Medicaid Services (CMS) may neither negotiate the prices of covered drugs nor establish a formulary. The bill repeals these restrictions and instead specifically requires the CMS to (1) negotiate the prices of covered drugs; and (2) either establish a formulary for covered drugs, or require changes to PDP formularies that take into account CMS negotiations. If the CMS is unable to negotiate an appropriate price for a drug in accordance with certain criteria, the price must be the lowest of three specified options (e.g., the average price in other countries). The CMS must identify drugs that are subject to negotiation, with priority given to certain categories of drugs based on usage and cost. Additionally, drug manufacturers must issue rebates to the CMS for drugs dispensed to eligible low-income individuals. Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.
Title
Medicare Drug Price Negotiation Act
Sponsors
Sen. Bernard Sanders [I-VT] | Sen. Cory Booker [D-NJ] | Sen. Kirsten Gillibrand [D-NY] | Sen. Kamala Harris [D-CA] |
Sen. Patrick Leahy [D-VT] | Sen. Jack Reed [D-RI] | Sen. Tina Smith [D-MN] | Sen. Elizabeth Warren [D-MA] |
Sen. Richard Blumenthal [D-CT] |
History
Date | Chamber | Action |
---|---|---|
2019-01-10 | Senate | Read twice and referred to the Committee on Finance. |
Same As/Similar To
HB448 (Same As) 2019-09-25 - Subcommittee Hearings Held.
Subjects
Congressional oversight
Government information and archives
Government studies and investigations
Health
Health care costs and insurance
Inflation and prices
Medicaid
Medicare
Prescription drugs
Public contracts and procurement
Retail and wholesale trades
Government information and archives
Government studies and investigations
Health
Health care costs and insurance
Inflation and prices
Medicaid
Medicare
Prescription drugs
Public contracts and procurement
Retail and wholesale trades
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/senate-bill/99/all-info |
Text | https://www.congress.gov/116/bills/s99/BILLS-116s99is.pdf |